Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC

EXOZYMES INC.

Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.
Concurrent private placement issued 93,750 warrants at $0.125, exercisable at $8.00 for 5 years.
Underwriter has 45-day option to purchase up to 281,250 additional shares for over-allotments.
Net proceeds to fund production capacity, business development, repayment of related-party loan, and working capital.
SAFEs from July 2023 converted into 125,001 shares of common stock upon IPO closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.